ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rosuvastatin

Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.

Drug pageRosuvastatin: every studyMany companies study it; this page follows only the 138 they lead. All 405 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 2005138 company-led studies, 7 open or runningNext primary completion: Jan 25, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca705 open or runningphase 4since Oct 7, 2005Sep 16, 2005Jan 25, 2027phase 1 · NCT07534592
Yuhanits history only100 open or runningphase 4since Jul 12, 2017Jan 5, 2012none ahead
Chong Kun Dang Pharmaceuticalits history only80 open or runningphase 2since Nov 27, 2016Jan 24, 2014none ahead
Organonits history only60 open or runningphase 4since Mar 31, 2008Aug 25, 2004none ahead
GlaxoSmithKlineits history only40 open or runningphase 1since Dec 18, 2008Dec 18, 2008none ahead
Merckits history only40 open or runningphase 3since Oct 10, 2025Jun 17, 2015none ahead
Hanlim Pharm.its history only30 open or runningphase 3since Jun 17, 2018Jun 17, 2018none ahead
IlDong Pharmaceuticalits history only30 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceuticalits history only30 open or runningphase 3since Jun 23, 2016Jul 4, 2014none ahead
Lotus Pharmaceuticalits history only30 open or runningphase 3since May 13, 2015Mar 4, 2014none ahead

Also a collaborator on its studies: Parexel, Pharma Medica Research, Pfizer, Regeneron Pharmaceuticals, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly, Linical Korea and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Oct 16, 2005.

  1. Nov 4, 2016Phase 1 study in High Risk Coronary Artery DiseaseNCT02963116 · 12 enrolled · United Kingdom
  2. Jan 11, 2017Phase 1 study in HealthyNCT03019549 · 42 enrolled · United States
  3. May 17, 2022Phase 1 study in DyslipidemiasNCT05384262 · 183 enrolled · United States, United Kingdom
  4. Mar 3, 2023Phase 1 study in Healthy Male SubjectsNCT05768360 · 6 enrolled · Germany
  5. Nov 29, 2023Phase 1 study in HealthyNCT06160414 · 20 enrolled · United Kingdom
  6. Aug 2, 2024Phase 1 study in Healthy ParticipantsNCT06554821 · 28 enrolled · Germany
  7. Dec 2, 2024Phase 3 study in DyslipidemiasNCT06834932 · 432 enrolled · China, Hong Kong
  8. Dec 16, 2024Phase 1 study in DyslipidemiasNCT06742853 · 81 enrolled · United States, United Kingdom
  9. Jul 17, 2025Phase 1 study in Healthy ParticipantsNCT07088913 · 20 enrolled · United States
  10. Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07316608 · 44 enrolled · United States
  11. Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07534592 · 48 enrolled · United States
  12. May 26, 20262 phase 3 studies in HypercholesterolemiaNCT07619131, NCT07619118
  13. Nov 5, 2026Phase 3 study in HypercholesterolemiaNCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
  14. Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592

Ahead

  1. Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07534592
  2. Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasNCT06834932
  3. May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619118
  4. Jul 30, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619131

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

The newest 60 of 70 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more3Not yet recruitingOct 11, 2027204
NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more3RecruitingJul 30, 2027600
NCT07619118Hypercholesterolemia · United States, Australia, Canada and more3RecruitingMay 28, 2027200
NCT07534592Diabetes Mellitus, Type 2 · United States1Active, not recruitingJan 25, 202748
NCT07316608Hyperlipidemias · United States1CompletedJun 5, 202644
NCT07088913Healthy Participants · United States1CompletedFeb 20, 202620
NCT06742853Dyslipidemias · United States, United Kingdom1CompletedOct 29, 202581
NCT06834932Dyslipidemias · China, Hong Kong3Active, not recruitingFeb 22, 2027432
NCT06554821Healthy Participants · Germany1CompletedOct 8, 202428
NCT06160414Healthy · United Kingdom1CompletedFeb 5, 202420
NCT05768360Healthy Male Subjects · Germany1CompletedJun 24, 20236
NCT05384262Dyslipidemias · United States, United Kingdom1CompletedJun 14, 2024183
NCT03019549Healthy · United States1CompletedMay 22, 201742
NCT02963116High Risk Coronary Artery Disease · United Kingdom1CompletedMar 1, 201712
NCT02859129Hypertriglyceridemia · United States1CompletedNov 2013114
NCT02546323Atherosclerosis · China3CompletedJan 29, 2019543
NCT02434497Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more3CompletedNov 17, 20169
NCT02226198Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more3CompletedJul 201520
NCT01164540Venous Thrombosis3WithdrawnMar 20133,000
NCT01078675Hyperlipoproteinemia Type II · United States, Belgium, Canada and more3CompletedFeb 2013315
NCT00815659Metabolic Syndrome · Turkey4CompletedMar 201097
NCT00800800Aortic Valve Stenosis · Canada3CompletedSep 2008378
NCT00783042Atherosclerosis · SwedenEarly 1Completed80
NCT00766025CYP2C19 Poor · Taiwan1Completed50
NCT00747149Diabetes Mellitus, Type 2 · Canada4CompletedAug 2009598
NCT00689416Atherosclerosis · SwedenEarly 1Completed74
NCT00683618Hypercholesterolemia · China3CompletedJul 2009934
NCT00657527Coronary Artery Disease3Completed280
NCT00654602Dyslipidemias3Completed1,500
NCT00654537Hypercholesterolemia3Completed5,625
NCT00654485Metabolic Syndrome3Completed940
NCT00654446Dyslipidemias3Completed442
NCT00654407Hypercholesterolemia3Completed4,875
NCT00654394Carotid Stenosis3Completed200
NCT00654303Hypercholesterolemia3Completed3,500
NCT00653588Hypercholesterolemia3Completed
NCT00653445Hypercholesterolemia3Completed
NCT00654225Hypercholesterolemia3Completed2,340
NCT00654173Hypercholesterolemia3Completed4,444
NCT00653965Hypercholesterolemia3Completed3,000
NCT00653744Hypercholesterolemia3Completed1,700
NCT00620542Coronary Artery Disease · United States, Argentina, Australia and more3CompletedJun 20112,333
NCT00525824Hypercholesterolemia · United States, Argentina, Brazil and more3CompletedSep 20081,743
NCT00473655Hypertriglyceridemia · Mexico4CompletedFeb 2009334
NCT00427960Hypercholesterolemia · United Kingdom4TerminatedFeb 200855
NCT00396240Hypercholesterolemia4Withdrawn1,294
NCT00395486Metabolic Syndrome · Korea, Republic of4CompletedJun 2008258
NCT00379249Hypercholesterolemia3Completed8,000
NCT00355615Hyperlipoproteinemia Type II · United States, Canada, Netherlands and more3CompletedJul 2008173
NCT00335699Hypercholesterolemia · Korea, Republic of4Completed370
NCT00329173Hypercholesterolemia3Completed1,000
NCT00329160Hypercholesterolemia · Japan4CompletedOct 2008214
NCT00296400Hyperlipidemias · United States, Brazil, Bulgaria and more2CompletedJun 2009237
NCT00296387Acute Coronary Syndrome · Belgium, Canada, Estonia and more3Completed1,160
NCT00296374Diabetes Mellitus · United States, Argentina, Brazil and more2CompletedMar 2009353
NCT00262548Diabetes Mellitus, Type 2 · Mexico4Completed100
NCT00241488Hypercholesterolemia · China, Hong Kong, Korea, Republic of and more3CompletedDec 20051,362
NCT00240331Renal Insufficiency · Australia, Austria, Belgium and more3CompletedOct 20082,776
NCT00240318Coronary Artery Disease · United States, Australia, Belgium and more3CompletedNov 2005450
NCT00240305Metabolic Syndrome · Australia3Completed15

How it is read

Names in the registry

  • “Rosuvastatin”, 105 entries
  • “rosuvastatin”, 10 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Rosuvastatin 20mg”, 6 entries
  • “Ezetimibe/Rosuvastatin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.